Abstract. Glycyrrhizic acid (GA) inhibits the activity of 11b-hydroxysteroid dehydrogenase type 2 in the kidney, with the resulting increase in intrarenal cortisol concentration leading to hypertension and suppression of the renin-aldosterone system. In this paper we describe an interesting case of pseudoaldosteronism, associated with hypocalcemia and an exaggerated ACTH response. A 72-year-old woman was referred to our department for further evaluation of hypokalemia and hypocalcemia. The patient had been taking GA (150 mg/day) for the previous year for treatment of liver damage. Plasma renin activity and aldosterone concentration were both within lower normal limits. Urinary excretion of potassium and calcium was within the upper limit of the normal range and increased with administration of supplements. Plasma ACTH levels increased markedly in response to an intravenous injection of CRH. Cessation of GA and the potassium and calcium supplements on admission, led to a gradual normalization of serum potassium and calcium levels and blood pressure. The hypocalcaemia in our patient was related to decreased tubular reabsorption of calcium as a consequence of renal corticoid excess. It is possible that an increase in the number of CRH receptors in the pituitary following GA treatment caused the exaggerated ACTH response in association with pseudoaldosteronism. The existence of hypocalcemia and an exaggerated ACTH response should be observed carefully when managing pseudoaldosteronism. GLYCYRRHIZIC acid (GA) inhibits the activity of 11b-hydroxysteroid dehydrogenase (11b-HSD) type 2, an enzyme that inactivates cortisol and allows selective access to the aldosterone receptor [1, 2] . The increased intrarenal concentration of cortisol resulting from inhibition of this enzyme causes stimulation of the mineralocorticoid receptor, leading to hypertension, hypokalemia, and suppression of the reninaldosterone system. As a consequence of these changes administration of GA causes pseudoaldosteronism [3] . A decrease in serum calcium concentration and increased urinary calcium excretion have been reported in primary aldosteronism and in glucocorticoid-treated patients [4, 5] . Significant changes in renal calcium handling in healthy volunteers have also been demonstrated following inhibition of 11b-HSD type 2 by GA [6] .
GLYCYRRHIZIC acid (GA) inhibits the activity of 11b-hydroxysteroid dehydrogenase (11b-HSD) type 2, an enzyme that inactivates cortisol and allows selective access to the aldosterone receptor [1, 2] . The increased intrarenal concentration of cortisol resulting from inhibition of this enzyme causes stimulation of the mineralocorticoid receptor, leading to hypertension, hypokalemia, and suppression of the reninaldosterone system. As a consequence of these changes administration of GA causes pseudoaldosteronism [3] .
A decrease in serum calcium concentration and increased urinary calcium excretion have been reported in primary aldosteronism and in glucocorticoid-treated patients [4, 5] . Significant changes in renal calcium handling in healthy volunteers have also been demonstrated following inhibition of 11b-HSD type 2 by GA [6] .
We describe an interesting case of pseudoaldosteronism, accompanied with hypocalcemia and an exaggerated ACTH response. The hypocalcemia and the exaggerated ACTH response to CRH both improved in parallel with normalization of hypokalemia and the renin-aldosterone system. These findings indicate that the hypocalcemia was related to decreased tubular reabsorption of calcium under conditions of renal corticoid excess [6] . We also speculate on the mechanism responsible for the exaggerated ACTH response in this case of pseudoaldosteronism.
Case report

Clinical summary
In January 2003, a 72-year-old woman was referred to our department for further evaluation of hypokalemia and hypocalcemia. A few years previously she had been diagnosed at a nearby hospital as having diabetes mellitus and liver damage. On admission to our hospital, her height was 141 cm, and body weight 51 kg, with a body mass index of 25.3 kg/m 2 . Blood pressure was 194/80 mmHg in spite of treatment with an angiotensin-converting enzyme inhibitor.
The results of biochemical analyses carried out at admission are summarized in Table 1 and show that liver and muscle enzymes were elevated, serum chloride, potassium, calcium, calcium ion (which could contain albumin-binding calcium), and phosphorus levels were all decreased, while the serum sodium level was within the normal limit. A specimen of arterial blood collected while the patient was on ventilation with 2 l/min of oxygen showed that oxygen saturation was 97%, oxygen partial pressure 86 mmHg, carbon dioxide partial pressure 57 mmHg and pH 7.50. Table  2a lists the results of the hormonal data and shows that plasma concentrations of ACTH and cortisol, and urinary excretion of free cortisol were within the normal ranges. Following an intravenous CRH injection there was a remarked increase in plasma ACTH levels and a mild elevation in cortisol levels (Fig. 1) . Both plasma ACTH and cortisol concentrations were suppressed completely by a low dose (0.5 and 1 mg) overnight dexamethasone suppression test (Table 2b) . Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) levels were both within the lower normal limit. The urinary excretion of potassium (50 mEq/day) and calcium (150 mEq/day) was within the normal upper limit and increased slightly, respectively, following intravenous supplementation (80 mEq/day for potassium and 7.5 mEq/day for calcium). The level of intact parathyroid hormone in the plasma was elevated. Computerized tomography scanning of the abdomen demonstrated no adrenal masses or abnormalities (not shown).
During the year prior to admission the patient had been taking GA (150 mg/day) for treatment of liver damage. Cessation of GA ingestion and also the potassium and calcium supplements on admission, led to gradual normalization of serum potassium and calcium levels and blood pressure. Two months later, all the time, the exaggerated ACTH response had also improved, while cortisol levels increased markedly in response to an intravenous injection of CRH (Fig. 1) .
Discussion
In this case, pseudoaldosteronism was caused by GA ingestion that had been administered to treat liver damage. The patient also had hypocalcemia. Plasma ACTH levels were increased markedly in response to an intravenous CRH injection, while cortisol levels were mildly elevated. The hypocalcemia and the exaggerated ACTH response improved in parallel with the patient's recovery from pseudoaldosteronism.
In our patient, pseudoaldosteronism was associated with hypocalcemia that in turn resulted in an increase in the level of intact parathyroid hormone level in the serum. Arterial blood gas analysis showed a metabolic alkalosis, consistent with pseudoaldosteronism. We consider it possible that the metabolic alkalosis decreased ionized calcium, with this change reflecting either altered calcium metabolism or an abnormal distribution of calcium between the extracellular and intracellular components [5, 7] . Urinary excretion of calcium was increased in our patient. This combination of reduced serum concentration and increased urinary excretion of calcium in primary aldosteronism and glucocorticoid-treated patients, suggests that overstimulation of mineralocorticoid receptor causes hypocalcemia [4, 5] . Inhibition of the 11b-HSD type 2 enzyme by GA also produces mineralocorticoid excess, and resulting in a decrease in serum calcium and an increase in urinary calcium excretion [6] . There is evidence that the 11b-HSD, mineralocorticoid receptor, and the thiazide-sensitive sodium-chloride cotransporter are all expressed in the distal convoluted tubule cells [8, 9] . A change in sodium transport in these cells has the potential to influence calcium ion transport [10, 11] and therefore it is possible that a decreased in the tubular reabsorption of calcium may cause hypocalcemia under conditions of renal corticoid excess [6] . Taken together these findings indicate that the presence of hypocalcemia, accompanied by hypokalemia, should be observed carefully when managing pseudoaldosteronism.
A recent study showed alterations in the pituitaryadrenal response in vivo in rats treated with GA [12] . On the basis of this result we carried out CRH tests to investigate the course of pseudoaldosteronism. We observed an exaggerated ACTH response in response to CRH in our patient similar to that described in the animal study. This response decreased in magnitude in parallel with the recovery of hypokalemia and the renin-aldosterone system. It has been reported that administration of GA decreases CRH release into the hypophysial portal blood without changing circulating glucocorticoid levels [13] . In this regard, Hanafusa et al. [12] found that mRNA expression and the levels of CRH in the hypothalamus did not change in GA-treated rats. This study, however, demonstrated up-regulation of CRH receptor mRNA and binding levels in the pituitary of the GA-treated animals, suggesting that GA enhanced the ACTH response to CRH by increasing the number and/or sensitivity of CRH receptors. Notwithstanding these findings, the mechanism responsible for the exaggerated ACTH response has yet to be conclusively established.
Our patient with pseudoaldosteronism had a mild increase in cortisol levels in response to CRH. We were not able to determine the reason for the discrepancy between the cortisol and ACTH responses in this case. Constant stimulation by cortisol would be expected to down-regulate the receptor or induce receptor insensitivity in the adrenal glands [14] . A high dose of glucocorticoids usually suppresses ACTH production in the pituitary. Therefore, cortisol increased locally following the inhibition of 11b-HSD type 2 may induce either mild insensitivity of the receptor or weak suppression of the adrenal glands [12] , which in turn alters the cortisol response in pseudoaldosteronism. Alternatively, the ACTH receptor or steroidogenetic enzymes may be modulated in GA-treated adrenal glands. Further studies are required to elucidate which mechanism was responsible for the changes observed in our patient.
In summary, we report an interesting case of pseudoaldosteronism, accompanied by hypocalcemia and an exaggerated ACTH response. In this patient decreased tubular reabsorption of calcium under conditions of renal cortisol excess may have caused hypocalcemia. In addition, an increase in either the number or sensitivity of CRH receptors in the pituitary with pseudoaldosteronism may have resulted in an exaggerated ACTH response. The existence of hypocalcemia and an exaggerated ACTH response should be observed carefully when managing pseudoaldosteronism.
